Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.36 |
| ▸ | CDK4 | P11802 | 6/20 | 0.36 |
| ▸ | CCND1 | P24385 | 6/20 | 0.36 |
| ▸ | CDK9 | P50750 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397176 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1CCNT1CDK4CCND1 | |
| SCHEMBL26515108 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1CCNT1CDK4CCND1 | |
| SCHEMBL21539305 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1CDK4CCND1ADORA2A | |
| SCHEMBL31559288 | 0.78 | EGFR (0.35) | SMN1; SMN2ADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL26515088 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1CCNT1CDK4CCND1 | |
| SCHEMBL20600776 | 0.77 | PRPS1 (0.44) | PRPS1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL16938822 | 0.75 | HCAR3 (0.43) | SMN1; SMN2CCNT1CDK4CCND1CDK9 | |
| SCHEMBL21522711 | 0.73 | NPC1 (0.37) | SMN1; SMN2PRPS1CDK4CCND1PI4KA | |
| SCHEMBL22598705 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1ADORA2AADORA2BADORA1 | |
| SCHEMBL31641849 | 0.72 | PRPS1 (0.46) | PRPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | Prelude Therapeutis Incorporated (US) | 2025-12-02 | — | — | US | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112313219-B | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3784664-A1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | Pfizer Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112313219-A | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3645536-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-05-06 | — | — | EP | disclosed |
| CN-110809577-A | Modulators of adenosine A2A receptor | 雷沃医疗有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766884-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885L3MBTL1 3915/4885PRPS1 2156/4885 |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885L3MBTL1 2377/4885PRPS1 1566/4885 |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885L3MBTL1 3915/4885PRPS1 2156/4885 |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885L3MBTL1 2377/4885PRPS1 1566/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885L3MBTL1 3915/4885PRPS1 2156/4885 |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885L3MBTL1 3915/4885PRPS1 2156/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885L3MBTL1 2377/4885PRPS1 1566/4885 |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3073/4885L3MBTL1 4882/4885PRPS1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.